Neuroprotection and dopamine agonists

Advances in Experimental Medicine and Biology

Volumn 541, Issue , 2003, Pages 55-74

  Pirtošek, Zvezdan ^a   Flisar, Dušan ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; APOMORPHINE; ASCORBIC ACID; BETA CAROTENE; BRAIN DERIVED NEUROTROPHIC FACTOR; CABERGOLINE; DEFEROXAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; LEVODOPA; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; PRAMIPEXOLE; RASAGILINE; REMACEMIDE; RILUZOLE; ROPINIROLE; SELEGILINE;

CHOREA MINOR; CHRONOPHARMACOLOGY; CLINICAL TRIAL; CONFERENCE PAPER; DIZZINESS; DOPAMINERGIC TRANSMISSION; DYSKINESIA; GENE THERAPY; HUMAN; INSOMNIA; LONG TERM CARE; NAUSEA; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SOMNOLENCE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL DEATH; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

LENTIVIRUS;

EID: 0347654946     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (128)

1. Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., and O'Brien, C. F. for the Ropinirole Study Group, 1997, Ropinirole for the treatment of early Parkinson's disease, Neurology. 49:393-399.
2. Ahlskog, J. E., 2003, Slowing Parkinson's disease progression: Recent dopamine agonist trials, Neurology. 60:381-389.
3. Appel, S. H., 1981, A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism and Alzheimer's disease, Ann Neurol. 10:499-505.
4. Asanuma, M., Ogawa, N., Nishibayashi, S., Kawai, M., Kondo, Y., and Iwata, E, 1995, Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain, Arch Int Pharmacodyn Ther. 329:221-230.
5. Ben-Shachar, D., Zuk, R., and Glinka, Y., 1995, Dopamine neurotoxicity: inhibition of mitochondrial respiration, J Neurochem. 64:718-723.
6. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenmyre, J. T., 2000, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat Neurosci. 3:1301-1306.
7. Blunt, S. B., Jenner, P., and Marsden, C. D., 1993, Suppressive effect of 1-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine, Mov Disord. 8:129-133.
8. Boomsma, F., Meerwaldt, J. D., Man in't Veld, A. J., Hoverstadt, A., and Schalekamp, M. A., 1989, Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa dexarboxylase, catecholamines and 3-O-methyl-dopa, J Neurol. 236:223-230.
9. Brooks, D. J., 1993, PET studies on the early and differential diagnosis of Parkinson's disease, Neurology. 43:S6-S16.
10. Carter, A. J., and Mueller, R. E., 1991, Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo, Eur J Pharmacol. 200:65-72.
11. Carvey, P. M., and Ling, Z., 2000, Pramipexole enhances Bcl-xl expression in mesencephalic cultures, Mov Dis. 15 Suppl. 3:17.
12. Cassarino, D. S., Fall, C. P., Smith, T. S., and Bennett, J. P. Jr., 1998, Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion, J Neurochem. 71:295-301.
13. Cheng, N., Maeda, T., Kume, T., Kaneko, S., Kochiyama, H., Akaike, A., Goshima, Y., and Misu, Y., 1996, Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons, Brain Res. 16;743:278-283.
14. Cotzias, G. C., Miller, S. T., Tang, L. C., and Papavasiliou, P. S., 1977, Levodopa, fertility, and longevity, Science. 196:549-551.
15. Desagher, S., Glowinski, J., and Premont, J., 1996, Astrocytes protect neurons from hydrogen peroxide toxicity, J Neurosci. 16:2553-2562.
16. Dexter, D. T., Wells, F. R., Agid, F., Less, A. J., Jenner, P., and Marsden, C. D., 1987, Increased iron content in post-mortem parkinsonian brain, Lancet. 2:1219-1220.
17. Dziewczapolski, G., Murer, G., Agid, Y., Gershanik, O., and Raisman-Vozari, R., 1997, Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats, Neuroreport. 8:975-979.
18. Ferger, B., Teismann, P., and Mierau, J., 2000, The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study, Brain Res. 883:216-223.
19. Fink, D. J., DeLuca, N. A., Yamada, M., Wolfe, D. P., and Glorioso, J. C., 2000, Design and application of HSV vectors for neuroprotection, Gene Ther. 7:115-119.
20. Finotti, N., Castagna, L., Moretti, A., and Marzatico, F., 2000, Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment, Pharmacol Res. 42:287-291.
21. Frucht, S., Rogers, J. D., Greene, P. E., Gordon, M. F., and Fahn, S., 1999, Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 52:1908-1910.
22. Gassen, M., Glinka, Y., Pinchasi, B., and Youdim, M. B., 1996, Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction, Eur J Pharmacol. 308:219-225.
23. Gassen, M., Gross, A., and Youdim, M. B., 1998, Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine, Mov Disord. 13:661-667.
24. Gassen, M., Gross, A., and Youdim, M. B., 1999, Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties, Adv Neurol. 80:297-302.
25. Gille, G., Rausch, W. D., Hung, S. T., Moldzio, R., Janetzky, B., Hundemer, H. P., Kolter, T., and Reichmann, H., 2002, Pergolide protects dopaminergic neurons in primary culture under stress conditions, J Neural Transm. 109:633-643.
26. Golbe, L. I., Di Iorio, G., Bonavita, V., Miller, D. C., and Duvoisin, R. C., 1990, A large kindred with autosomal dominant Parkinson's disease, Ann Neurol. 27:276-228.
27. Gomez-Vargas, M., Nishibayashi-Asanuma, S., Asanuma, M., Kondo, Y., Iwata, E., and Ogawa, N., 1998, Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain, Brain Res. 790:202-208.
28. Goshima, Y., Ohno, K., Nakamura, S., Miyamae, T., Misu, Y., and Akaike, A., 1993, L-dopa induces Ca(2+)-dependent and tetrodotoxin-sensitive release of endogenous glutamate from rat striatal slices, Brain Res. 16:167-170.
29. Graham, D. G., 1978, Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones, Mol Pharmacol. 14:633-643.
30. Grunblatt, E., Mandel, S., Berkuzki, T., and Youdim, M. B., 1999, Apomorphine protects against MPTP-induced neurotoxicity in mice, Mov Disord. 14:612-618.
31. Grunblatt, E., Mandel, S., Maor, G., and Youdim, M. B., 2001, Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss, J Neurochem. 77:146-156.
32. Guttman, M., and the International Pramipexole-Bromocriptine Study Group, 1997, Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease, Neurology. 49:1060-1065.
33. Hall E. D., Andrus P. K., Oostveen J. A., Althaus J. S., and VonVoigtlander P. F., 1996, Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons, Brain Res. 742:80-88.
34. Han, S. K., Mytilineou, C., and Cohen, G., 1996, L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress, J Neurochem. 66:501-510.
35. Hefti, F., Melamed, E., Bhawan, J., and Wurtman, R., 1981, Long term administration of 1-dopa does not damage dopaminergic neurons in the mouse, Neurology. 31:1194-1195.
36. Hernan, M. A., Takkouche, B., Caamano-Isoma, F., and Gestal-Otero, J. J., 2002, A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease, Ann Neurol. 52:276-284.
37. Hirsch, E. C., Hunot, S., Damier, P., and Faucheux, B., 1998, Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol. 44:S115-S120.
38. Homann, C. N., Wenzel, K., Suppan, K., Ivanic, G., Kriechbaum, N., Crevenna, R., and Ott, E., 2002, Sleep attacks in patients taking dopamine agonists: review. BMJ. 324:1483-1487.
39. Hubble, J. P., Koller, W. C., Cutler, N. R., Sramek, J. J., Friedman, J., Goetz, C., Ranhosky, A., Korts, D., and Elvin, A., 1995, Pramipexole in patients with early Parkinson's disease, Clin Neuropharmacol. 18:338-347.
40. Iida, M., Miyazaki, I., Tanaka, K., Kabuto, H., Iwata-Ichikawa, E., and Ogawa, N., 1999, Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist, Brain Res. 838:51-59.
41. Ishikawa, A., and Tsuji, S., 1996, Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism, Neurology. 47:160-166.
42. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A., and Saitoh, T., 1995, The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system, Neuron. 14:467-475.
43. Jenner, P., 1991, Oxidative stress as a cause of Parkinson's disease, Acta Neurol Scand Suppl 136:6-15.
44. Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. V., and Marsden, C. D., 1992, Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease, Ann Neurol. 32 (Suppl):S82-S87.
45. Kebabian, J. W., and Calne, D. G., 1979, Multiple receptors for dopamine, Nature. 277:93-96.
46. Kimmel, H. L., Yoyce, A. R., Carroll, F. I., and Kuhar, M. J., 2001, Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat, J Pharmacol Exp Ther. 298:129-140.
47. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N., 1998, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature. 392:605-608.
48. Kitamura, Y., Shimohama S., Kamoshima, W., Ota, T., Matsuoka, Y., Nomura, Y., Smith, M. A., Perry, G., Whitehouse, P. J., and Taniguchi, T., 1998, Alterations of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-I and CPP32, in Alzheimer's disease. Brain Res. 780:260-269.
49. Kordower, J. H., Emborg, M. E., Bloch, J., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E. Y., Palfi, S., Roitberg, B. Z., Brown, W. D., Holden, J. E., Pyzalski, R., Taylor, M. D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N., and Aebischer, P., 2000, Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease, Science. 290:767-773.
50. Korsching, S., 1993, The neurotrophic factor concept: a reexamination, J Neurosci 13:2739-2748.
51. Kreiss, D. S., Bergstrom, D. A., Gonzalez, A. M., Huang, K. X., Sibley, D. R., and Walters, J. R., 1995, Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities, Eur J Pharmacol. 227:209-214.
52. Kumar, R., Agarwal, A. K., and Seth, P. K., 1995, Free radical-generated neurotoxicity of 6-hydroxydopamine, J Neurochem. 65:1906.
53. Lee, C. S., Samii, and A., Sossi, V., 2000, In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease, Ann Neurol. 47:493-503.
54. Ling, Z. D., Robie, H. C., Tong, C. W., and Carvey, P. M., 1999, Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther. 289:203-210.
55. Lieberman, A., Ranhosky, A., and Korts, D., 1997, Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study, Neurology. 49:1162-1168.
56. Lieberman, A., Olanow, C. W., Sethi K., Swanson, P., Waters, C. H., Fahn, S., Hurtig, H., Yahr, M., and the Ropinirole Study Group, 1998, A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease, Neurology. 51:1057-1062.
57. Maier Hoehn, M. M., 1983, Parkinsonism treated with levodopa: progression and mortality, J Neural Transm Suppl. 19:253-264.
58. Masserano, J. M., Gong, L., Kulaga, H., Baker, I., and Wyatt, R. J., 1996, Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system, Mol Pharmacol. 50(5):1309-1315.
59. Matsumine, H., Saito, M., Shimoda-Matsubayashi, S., Tanaka, H., Ishikawa, A., Nakagawa-Hattori, Y., Yokochi, M., Kobayashi, T., Igarashi, S., Takano, H., Sanpei, K., Koike, R., Mori, H., Kondo, T., Mizutani, Y., Schaffer, A. A., Yamamura, Y., Nakamura, S., Kuzuhara, S., Tsuji, S., and Mizuno, Y., 1997, Localization of a gene for an abnormal recessive form of juvenile Parkinsonism to chromosome 6q25. 2-27, Am J Hum Genet. 60:588-596.
60. McGeer, P. L., Itagaki, S., Boyes, B. E., and McGeer, E. G., 1988, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology. 38:1285-1291.
61. Melamed, E., Offen, D., Shirvan, A., Djaldetti, R., Barzilai, A., and Ziv, I., 1998, Levodopa toxicity and apoptosis, Ann Neurol. 44:S149-154.
62. Mena, M. A., Davila, V., and Sulzer, D., 1997, Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures, J Neurochem. 69:1398-1408.
63. Michel, P. P., and Hefti, F., 1990, Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture, J Neurosci Res. 26:428-435.
64. Montastruc, J. L., Rascol, O., Senard, J. M., and Rascol, A., 1994, A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previouly untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry. 57:1034-1038.
65. Muralikrishnan, D., and Mohanakumar, K. P., 1998, Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice, FASEB J. 12:905-912
66. Murer, M. G., Dziewczapolski, G., Menalled, L. B., Garcia, M. C., Agid, Y., Gershanik, O., and Raisman-Vozari, R., 1998, Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions, Ann Neurol. 43:561-575.
67. Mytilineou, C., Han, S. K., and Cohen, G., 1993, Toxic and protective effects of L-dopa on mesencephalic cell cultures, J Neurochem. 61:1470-1478.
68. Naoi, M., Dostert, P., Yoshida, M., and Nagatsu, T., N-methylated tetrahydro-isoquinolines as dopaminergic neurotoxins, Adv Neurol 60:212-217.
69. Nishibayashi, S., Asanuma, M., Kohno, M., Gomez-Vargas, M., and Ogawa, N., 1996, Scavenging effects of dopamine agonists on nitric oxide radicals, J Neurochem. 67:2208-2211.
70. Noh, J. S. and Gwag, B. J., 1997, Attenuation of oxidative neuronal necrosis by a dopamine D1 agonist in mouse cortical cell cultures, Exp Neurol. 146:604-608.
71. Offen, D., Ziv, I., Stemin, H., Melamed, E., and Hochman, A., 1996, Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease, Exp Neurol. 141:32-39.
72. Offen, D., Beart, P. M., Cheung, N. S., Pascoe, C. J., Hochman, A., Gorodin, S., Melamed, E., Bernard, R., and Bernard, O., 1998, Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity, Proc Natl Acad Sci USA. 12:5789-5794.
73. Offen, D., Ziv, I., Panet, H., Wasserman, L., Stein, R., Melamed, E., and Barzilai, A., 1997, Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2. Cell Mol Neurobiol. 17:289-304.
74. Ogawa, N., Asanuma, M., Kondo, Y., Kawada, Y, Yamamoto, M., and Mori, A., 1994a, Differential effects of chronic 1-DOPA treatment on lipid peroxidation in the mouse brain with and without pretreatment with 6-hydroxydopamine, Neurosci Lett. 171:55-58.
75. Ogawa, N., Tanaka, K., Asanuma, M., Kawai, M., Masumizu, T., Kohno, M., and Mori, A., 1994b, Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro, Brain Res. 657:207-213.
76. Olanow, C. W., Fahn, S., Muenter, M, Klawans, H., Hurtig, H., Stern, M., Shoulson, I., Kurlan, R., Grimes, J. D., Jankovic, J., Hoehn, M., Marham, C. H., Duvoisin, R., Reinmuth, O., Leonard, H. A., Ahlskog, E., Feldman, R., Hershey, L., and Yahr, M. D., 1994, A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease. Mov Disord. 9:40-47.
77. Olanow, C. V., Hauser R. A., Gauger, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., and Esterlitz, J., 1995, The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol. 38:771-777.
78. Papavasiliou, P. S., Miller, S. T., Thal, L. J., Nerder, L. J., Houlihan, G., Rao, S. N., and Stevens, J. M., 1981, Age-related motor and catecholamine alterations in mice on levodopa supplemented diet, Life Sci. 28:2945-2952.
79. Pardo, B., Mena, M. A., Fahn, S., and De Yebenes, J. G., 1993, Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord. 8:278-284.
80. Pardo, B., Mena, M. A., Casarejos, M. J., Paino, C. L., and De Yebenes, J. G., 1995a, Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 5:133-143.
81. Pardo, B., Mena, M. A., and de Yebenes, J. G., 1995b, L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells, J Neurochem. 64:576-582.
82. Parkinson, J., 1819, An Essay on the Shaking Palsy, Sherwood, Neely and Jones, London.
83. Parkinson Study Group, 2000, Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomised controlled trial, JAMA. 284:1931-1938.
84. Parkinson Study Group, 2002, Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression, JAMA. 287:1653-1661.
85. Pelton, E. W. 2nd, Kimelberg, H. K., Shipherd, S. V., and Bourke, R. S., 1981, Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture, Life Sci. 28:1655-1663.
86. Perry, T. L., Young, V. W., Ito, M., Foulks, J. G., Wall, R. A., Godin, D. V., and Clavier, R. M., 1984, Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of 1-dopa and carbidopa chronically, J Neurochem. 43:990-993.
87. Piercey, M. F., Camacho-Ochoa, M., and Smith, M. W., 1995, Functional roles for dopamine-receptor subtypes, Clin Neuropharmacol. 18:34-42.
88. Pinter, M. M., Pogarell, O., and Oertel, W. M., 1999, Efficacy, safety and tolerance of the non-ergoline agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo controlled, randomised, multicentre study, J Neuro Neurosurg Psychiatry. 66:436-441.
89. Polymeropoulos, M. H., Higgins, J. J., Golbe, L. I., Johnson, W. G., Ide, S. E., Di Iorio, G., Sanges, G., Stenroos, E. S., Pho, L. T., Schaffer, A. A., Lazzarini, A. M., Nussbaum, R. L., and Duvoisin, R. C., 1996, Mapping of a gene for Parkinson's disease to chromosome 4q21-q23, Science. 274:1197-1199.
90. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L., 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science. 276:2045-2047.
91. Pothos, E. N., Przedborski, S., Davila, V., Schmitz, Y., and Sulzer, D., 1998, D2-Like dopamine autoreceptor activation reduces quantal size in PC12 cells, J Neurosci. 18:5575-5585.
92. Przedborski, S., Jackson-Lewis, V., Muthane, U., Jiang, H., Ferreira, M, Naini, A. B., and Fahn, S., 1993, Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity, Ann Neurol. 34:715-723.
93. Przedborski, S., and Jackson-Lewis, V., 1998, Mechanisms of MPTP toxicity., Mov Disord. 13:35-38.
94. Quinn, N., Parkes, J. D., Janota, I., and Marsden, C. D., 1986, Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four year period, Mov Disord. 1:65-68.
95. Rajput, A. H., Fenton, M., Birdi, S., and Macaulay, R., Is levodopa toxic to human substantia nigra? Mov Disord. 12:634-638.
96. Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., and Lang, A. E., for the 056 Study Group, 2000, A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa, N Engl J Med. 342:1484-1491.
97. Rinne, U. K., 1983, Problems associated with long-term levodopa treatment of Parkinson's disease, Acta Neurol Scand. 95:19-26.
98. Rioux, L., Frohna, P. A., Joyce, J. N., and Schneider, J. S., 1997, The effects of chronic levodopa treatment on pre-and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys, Mov Disord. 12:148-158.
99. Saggu, H., Cooksey, J., Dexter, D., Wells, F. R., Lees, A., Jenner, P., and Marsden, C. D., 1989, A selective increase in particular superoxide dismutase activity in Parkinson's substantia nigra, J Neurochem. 53:692-697.
100. Saji, L. M., Blau, A. D., and Volpe, B. T., 1996, Prevention of transneuronal degeneration of neurons in the substantia nigra reticulate by ablation of the subthalamic nucleus, Exp Neurol. 141:120-129.
101. Sampaio-Maia, B., Serrao, M. P., and Soares-Da-Silva, P., 2001, Regulatory path-ways and uptake of 1-dopa by capillary cerebral endothelial cells, astrocytes and neuronal cells, Am J Phisiol Cell Physiol. 280:C333-C342.
102. Sanchez-Ramos, J., Overvuk, E., and Ames, B. N., 1994, A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain, Neurodegeneration. 3:197-204.
103. Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., and Marsden, C. D., 1989, Mitochondrial complex 1 deficiency in Parkinson's disease, Lancet. 1:1269.
104. Schapira, A. H. V., 2002a, Neuroprotection and dopamine agonists, Neurology. 58:S9-S18.
105. Schapira, A. H. V., 2002b, Dopamine agonists and neuroprotection in Parkinson's disease, Eur J Neurol 9:1-6.
106. Schwab, R. S., Amador, L. V., and Levine, J. Y., 1951, Apomorphine in Parkinson's disease, Trans Am Neurol Assoc. 76:273-279.
107. Schwartz, J. C., Giros, B., Martres, M. P., and Sokoloff, P., 1992. The dopamine receptor family: molecular biology and pharmacology, Semin Neurosci. 4:99-108.
108. Semchuk, K. M., Love, E. J., and Lee, R. G., 1992, Parkinson's disease and exposure to agriculture work and pesticide chemicals, Neurology. 42:1328-1335.
109. Sethy, V. H., Wu, H., Oostveen, J. A., and Hall, E. D., 1997, Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acerylpyridine-treated rats, Brain Res. 754:181-186.
110. Shannon, K. M., Bennett, J. P., and Friedman, J. H., for the Pramipexole Study Group 1997, Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease, Neurology. 49:724-728.
111. Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., and Marsden, C. D., 1994, Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia, Ann Neurol. 36:348-355.
112. Sotnikova, T. D., Gainetdinov, R. R., Grekhova, T. V., and Rayevsky, K. S., 2001, Effects of intrastriatal infusion of D2 and D3 receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study), Pharmacol Res. 43:283-290.
113. Spencer, J. P. E., Jenner, A., Aruoma, O. I., Evans, P. J., Kaur, H., Dexter, D. T., Jenner, P., Lees, A. J., Marsden, D. C., and Halliwell, B., 1994, Intense oxidative DNA damage promoted by 1-DOPA and its metabolites: implications for neurodegenerative disease, FEBS Lett. 353:246-250.
114. Spencer-Smith, T., Parker, W. D. Jr, and Bennett, J. P., 1994, L-DOPA increases nigral production of hydroxyl radicals in vivo: potential 1-DOPA toxicity?, NeuroReport. 5:1009-1011.
115. Spina, M. B., and Cohen, G., 1988, Exposure of striatal synaptosomes to levodopa elevates levels of oxidized glutathione, J Pharmacol Exp Ther. 247:502-507.
116. Stocchi, F., Nordera, G., and Marsden, C. D., 1997, Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias, Clin Neuropharmacol. 20:95-115.
117. Tanaka, M., Sotomatsu, A., Kanai, H., and Hirai, S., 1991, Dopa and dopamine cause cultured neuronal death in the presence of iron, J Neurosci. 101:198-203.
118. Tanaka, M., Sotomatsu, A., Kanai, H., and Hirai, S., 1992, Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by DOPA and iron, Neurosci Lett. 140:42-46.
119. Tanaka, K., Miyazaki, I., Fujita, N., Haque, M. E., Asanuma, M., and Ogawa, N., 2001, Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist, Neurochem Res. 26:31-36.
120. Takata, K., Kitamura, Y., Kakimura, J., Kohno, Y., and Taniguchi, T., 2000, Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole, Brain Res. 872:236-241.
121. Tipton, K. F., and Singer, T., 1993, Advances in our understanding of the mechanism of the neurotoxicity of MPTP and related compounds, J Neurochem. 61:1191-1206.
122. Ubeda, A., Montesinos, C., Paya, M., and Alcaraz, M. J., 1993, Iron-reducing and free-radical scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic Biol Med. 15:159-167.
123. Weill, E., 1884, De l'apomorphine dans certains troubles nerveux. Lyon Med. 48:411-419
124. Whone, A. L., Remy, P., Davis, M. R., Sabolek, M., Nahmias, C., A. Stoessl, J., Watts, R. L., and Brooks, D. J., 2002, The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with 1-dopa, Neurology. 58:A82-A83.
125. Yee, R. E., Cheng, D. W., Huang, S. C., Namavari, M., Satyamurthy, N., and Barrio, J. R., 2001, Blood-brain barrier neuronal membrane transport of 6-[18F]fluoro-L-DOPA, Biochem Pharmacol. 62:1409-1415.
126. Yoshioka, M., Tanaka, K., Miyazaki, I., Fujita, N., Higashi, Y., Asanuma, M., and Ogawa, N., 2002, The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals, Neurosci Res. 43:259-267.
127. Youdim, M. B., Gassen, M., Gross, A., Mandel, S., and Grunblatt, E., 2000, Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine, J Neural Transm. 58:83-96.
128. Zou, L., Jankovic, J., Rowe, D. B., Xie, W., Appel, S. H., and Le, W., 1999, Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity, Life Sci. 64:1275-1285.